A platform technology for drug development has produced positive in vivo results treating cognition/memory loss while also treating anxiety.
ADispell is dedicated to rapidly advancing a new therapeutic platform technology to treat devastating memory-loss conditions while also positively affecting anxiety. We have 3 lead compounds. The compounds produced positive in vivo results for memory loss and improved learning, successfully crossed the blood-brain barrier, is a vasodilator, and is safe. Our development work is well advanced and involves a new approach that favors neuron health.